Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Invasive Breast Cancer
Interventions: DRUG: Cemiplimab|DRUG: Paclitaxel|DRUG: Carboplatin (not mandatory)|DRUG: Doxorubicin|DRUG: Cyclophosphamide
Sponsor: Medical College of Wisconsin